BioSpace News Archive

AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1

Arsenal Medical today announced enrollment of the first patient with the company’s investigational NeoCast™ embolic biomaterial.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key complex generic products.

Circle Pharma announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer.

Sensus Healthcare, Inc. announces that management will hold a conference call on Thursday, August 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2023.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023.

ABVC BioPharma, Inc. announced that it has signed a term sheet to advance a partnership with Zhonghui United Technology Group Co., Ltd. and its affiliated enterprises.

LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.

Lucid Diagnostics Inc. today announced that Shaun O’Neil, Executive Vice President & Chief Operating Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 11:30 am Eastern Time at the InterContinental Boston Hotel in Boston, MA.

Soin Neuroscience has announced that it has tested its TunedTX platform using very low frequency stimulation.